The privately-held Swiss biotechnology company OncoEthix SA has raised CHF 18 million ($19 million) from venture capitalists to progress its lead oncology compound into Phase 2 studies. The compound targets a class of bromodomain proteins. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
